Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New support program aims to help breast cancer patients stick with treatment

NCT ID NCT06983691

First seen Mar 12, 2026 · Last updated Jun 23, 2026 · Updated 9 times

Summary

This study tests a nurse-led patient navigation program for 26 women with HER2+ metastatic breast cancer who are taking a specific combination of drugs. The program provides education, symptom management tips, and coping strategies over about 12 weeks. Researchers want to see if the program is practical and well-liked by patients, not whether it changes the cancer itself.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2+ METASTATIC BREAST CANCER (MBC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Patient Navigation Program (behavioral intervention)

What this could lead to

If it works, this program could become a standard support tool to help women with metastatic breast cancer better manage their treatment and side effects.

What could go wrong

This is a very small, early feasibility study with only 26 participants. It is not designed to prove the program improves health outcomes, only that it is acceptable and practical.

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.